IAM-1363

N/A

Report date: 2026/04/14 20:00:15
NME

Base Information

Drug NameIAM-1363
Drug Alias NameIAM1363IAM-1363IAM-H1ENT-H1
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumoursCentral Nervous System DiseasesNeoplasm Metastasis +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsItaly +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIambic Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesIambic Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCentral Nervous System DiseasesNeoplasm Metastasis +[8] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A